Bluejay Diagnostics Inc (BJDX)

$0.91 -0.01 (-0.87%)
Market Cap 4.11M
Revenue (ttm) 0.00
Net Income (ttm) -6.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 214,273
Avg Vol 4,327,960
Day's Range N/A - N/A
Shares Out 4.47M
Stochastic %K 41%
Beta 0.91
Analysts Strong Buy
Price Target $32.00

Company Profile

Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force. The company also develops Symphony IL-6 tests fo...

Industry: Medical Devices
Sector: Healthcare
Phone: 844 327 7078
Address:
360 Massachusetts Avenue, Suite 203, Acton, United States
sSwSs
sSwSs Sep. 21 at 2:57 PM
$BJDX — Bluejay Diagnostics' Symphony IL-6 product advancement and clinical study milestones contrasted with persistent financial losses and bearish technical indicators. Upside discussed: Successful completion of enrollment in the SYMON-II clinical validation study. Strengthened balance sheet to support product advancement. Risk discussed: Consistent net losses and operating losses reported annually and quarterly. Zero reported revenue and gross profit for fiscal years 2022 and 2023. Recent analyses for Bluejay Diagnostics (BJDX) covered the advancement of its Symphony™ IL-6 product towards regulatory submission, supported by a strengthened balance sheet and the successful completion of the SYMON-II clinical validation study. Concurrently, the analyses noted the company's consistent net losses, lack of revenue, and significant bearish technical indicators including prices below key moving averages and negative MACD readings.
0 · Reply
OnlyFibs
OnlyFibs Sep. 20 at 11:08 PM
$BJDX | Snapshot 📊🧪• Business: Near-patient diagnostic medical technology developer advancing the proprietary Symphony System for rapid whole-blood biomarker testing in critical care settings.• Financial Health & Pipeline: Completed enrollment in the pivotal SYMON-II clinical trial for its lead Symphony IL-6 sepsis risk test ahead of planned FDA 510(k) submission.• Bias & Conviction: Bottoming Watch | Speculative Conviction (Monitoring for a reclaim of $1.02 volume resistance following extended range contraction near $0.80 support). 🎯 Key Levels: 🐂 Bull Trigger: $1.02 / $1.25 🚀 Targets: $1.45 / $2.00 / $2.52 🛡️ Support: $0.89 / $0.80 ⚠️ Risk: $0.80 / $0.67 #BJDX #biotech #medtech #finance #hovdid
0 · Reply
STOCKSGambino
STOCKSGambino Sep. 18 at 9:24 PM
$BJDX https://x.com/StocksGambino/status/2101059714691780913
0 · Reply
azzaro2ke
azzaro2ke Sep. 18 at 8:16 PM
$BJDX 1.3?
0 · Reply
STOCKSGambino
STOCKSGambino Sep. 18 at 7:29 PM
$BJDX https://x.com/StocksGambino/status/2101029367602409536
1 · Reply
STOCKSGambino
STOCKSGambino Sep. 18 at 2:22 PM
$BJDX https://x.com/StocksGambino/status/2100953516265107628
0 · Reply
martyn78
martyn78 Sep. 16 at 7:53 AM
Been tapped into @_ProfessorGamma for a minute now. The way they spot some of these plays before they run is nuts! Wise to be paying attention to this account, give him a proper follow 👍 $NUWE / $BJDX watching
0 · Reply
PrintingGains
PrintingGains Sep. 11 at 6:39 PM
$BJDX round 2?
0 · Reply
Fsrwish
Fsrwish Sep. 11 at 3:44 PM
$BJDX sad, loose the momentum! Another reverse split?
1 · Reply
StockSenseiTrendTraders
StockSenseiTrendTraders Sep. 9 at 10:54 PM
Slow last week, slow again so far this week. There is a reason for it. PPI comes tomorrow, CPI on Friday, and FOMC is next week. A lot of traders are parked on the sidelines waiting on that outcome, and thin participation shows up in small caps immediately. $SUNE, $OLB, $MOBX, $BJDX and $YMAT still delivered. Eleven winners on twelve alerts.
0 · Reply
Latest News on BJDX
Bluejay Diagnostics and Lovell Government partner to access federal healthcare

2026-09-08T10:35:07.000Z - 13 days ago

Bluejay Diagnostics and Lovell Government partner to access federal healthcare

Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets

Sep 8, 2026, 6:30 AM EDT - 13 days ago

Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets

Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization

Aug 13, 2026, 6:00 AM EDT - 5 weeks ago

Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization

Bluejay Diagnostics completes enrollment in SYMON-II study

2026-07-21T10:35:18.000Z - 2 months ago

Bluejay Diagnostics completes enrollment in SYMON-II study

Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study

Jul 21, 2026, 6:30 AM EDT - 2 months ago

Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study

Bluejay Diagnostics files to sell 11.22M shares of common stock for holders

2026-06-17T21:25:09.000Z - 3 months ago

Bluejay Diagnostics files to sell 11.22M shares of common stock for holders

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Jun 5, 2026, 8:13 PM EDT - 3 months ago

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Jun 2, 2026, 12:19 PM EDT - 3 months ago

Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Why Is Penny Stock Bluejay Diagnostics (BJDX) Up Today?

2026-06-02T13:13:16.000Z - 3 months ago

Why Is Penny Stock Bluejay Diagnostics (BJDX) Up Today?

Bluejay Diagnostics, Argonaut Manufacturing Services announce partnership

2026-06-02T10:45:59.000Z - 3 months ago

Bluejay Diagnostics, Argonaut Manufacturing Services announce partnership

Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership

Jun 2, 2026, 6:30 AM EDT - 3 months ago

Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership

Bluejay Diagnostics Provides First Quarter 2026 Corporate Update

May 7, 2026, 4:01 PM EDT - 4 months ago

Bluejay Diagnostics Provides First Quarter 2026 Corporate Update

Bluejay Diagnostics reaches 624 patient enrollment in Symphony clinical trial

2026-04-07T10:45:34.000Z - 5 months ago

Bluejay Diagnostics reaches 624 patient enrollment in Symphony clinical trial

Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial

Apr 7, 2026, 6:30 AM EDT - 5 months ago

Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial

Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting

Mar 12, 2026, 6:30 AM EDT - 6 months ago

Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting

NorthStrive Fund urges Bluejay to evaluate strategic opportunity

2026-03-11T13:35:11.000Z - 6 months ago

NorthStrive Fund urges Bluejay to evaluate strategic opportunity

NorthStrive Fund II LP Issues Open Letter to the Board and Shareholders of Bluejay Diagnostics

Mar 11, 2026, 9:29 AM EDT - 6 months ago

NorthStrive Fund II LP Issues Open Letter to the Board and Shareholders of Bluejay Diagnostics

Bluejay Diagnostics says SYMON II study ‘progressing as planned’

2026-03-06T11:41:51.000Z - 6 months ago

Bluejay Diagnostics says SYMON II study ‘progressing as planned’

Bluejay Diagnostics Announces All Prefunded Warrants Now Exercised

Feb 20, 2026, 6:30 AM EST - 7 months ago

Bluejay Diagnostics Announces All Prefunded Warrants Now Exercised

Bluejay Diagnostics enrolls 545 patients in SYMON II study

2026-02-17T11:45:15.000Z - 7 months ago

Bluejay Diagnostics enrolls 545 patients in SYMON II study

Bluejay Diagnostics Successfully Enrolls 545 Patients in SYMON™ II Study and Advances Manufacturing Readiness into 2026

Feb 17, 2026, 6:30 AM EST - 7 months ago

Bluejay Diagnostics Successfully Enrolls 545 Patients in SYMON™ II Study and Advances Manufacturing Readiness into 2026

Bluejay Diagnostics Inc trading halted, news pending

2026-01-29T00:50:10.000Z - 7 months ago

Bluejay Diagnostics Inc trading halted, news pending

Bluejay Diagnostics announces 1-for-4 reverse stock split

2026-01-27T13:10:41.000Z - 7 months ago

Bluejay Diagnostics announces 1-for-4 reverse stock split

Bluejay Diagnostics completes commercial-scale IL-6 antibody production

2025-12-29T12:05:14.000Z - 8 months ago

Bluejay Diagnostics completes commercial-scale IL-6 antibody production

Bluejay Diagnostics Announces Completion of Commercial-Scale IL-6 Antibody Production

Dec 29, 2025, 7:00 AM EST - 8 months ago

Bluejay Diagnostics Announces Completion of Commercial-Scale IL-6 Antibody Production

Bluejay Diagnostics provides Q3 corporate update

2025-11-10T12:55:58.000Z - 10 months ago

Bluejay Diagnostics provides Q3 corporate update

Bluejay Diagnostics files to sell 6.93M shares of common stock for holders

2025-10-23T21:05:24.000Z - 11 months ago

Bluejay Diagnostics files to sell 6.93M shares of common stock for holders

Bluejay Diagnostics Announces Closing of $4.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Oct 10, 2025, 5:16 PM EDT - 11 months ago

Bluejay Diagnostics Announces Closing of $4.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Bluejay Diagnostics announces $4.5M private placement priced at-the-market

2025-10-09T19:20:15.000Z - 11 months ago

Bluejay Diagnostics announces $4.5M private placement priced at-the-market

Bluejay Diagnostics Announces $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Oct 9, 2025, 3:15 PM EDT - 11 months ago

Bluejay Diagnostics Announces $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Why Is Bluejay Diagnostics Stock (BJDX) Up 115% Today?

2025-10-09T12:11:30.000Z - 11 months ago

Why Is Bluejay Diagnostics Stock (BJDX) Up 115% Today?

Bluejay Diagnostics and SanyoSeiko expand partnership for Symphony platform

2025-10-09T10:35:27.000Z - 11 months ago

Bluejay Diagnostics and SanyoSeiko expand partnership for Symphony platform

Bluejay Diagnostics and SanyoSeiko Expand Strategic Partnership to Advance Commercialization of Symphony Platform

Oct 9, 2025, 6:30 AM EDT - 11 months ago

Bluejay Diagnostics and SanyoSeiko Expand Strategic Partnership to Advance Commercialization of Symphony Platform

Bluejay Diagnostics Provides Second Quarter Business and Corporate Update

Aug 7, 2025, 6:30 PM EDT - 1 year ago

Bluejay Diagnostics Provides Second Quarter Business and Corporate Update

Bluejay Diagnostics provides corporate update, reduces headcount to five

2025-06-03T20:20:12.000Z - 1 year ago

Bluejay Diagnostics provides corporate update, reduces headcount to five

Bluejay Diagnostics Provides Mid-Year Business and Corporate Update

Jun 3, 2025, 4:05 PM EDT - 1 year ago

Bluejay Diagnostics Provides Mid-Year Business and Corporate Update

Bluejay Announces Abstract Accepted for Presentation at the 2025 Society of Academic Emergency Medicine (SAEM) Annual Meeting

Apr 15, 2025, 7:00 AM EDT - 1 year ago

Bluejay Announces Abstract Accepted for Presentation at the 2025 Society of Academic Emergency Medicine (SAEM) Annual Meeting

Bluejay Diagnostics Announces Entry into Warrant Inducement Transaction for Approximately $3.7 Million in Gross Proceeds

Apr 7, 2025, 5:21 PM EDT - 1 year ago

Bluejay Diagnostics Announces Entry into Warrant Inducement Transaction for Approximately $3.7 Million in Gross Proceeds

Bluejay Diagnostics Announces Reverse Stock Split

Nov 13, 2024, 5:10 PM EST - 1 year ago

Bluejay Diagnostics Announces Reverse Stock Split

Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering

Jun 28, 2024, 11:32 AM EDT - 2 years ago

Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering

SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients

Jun 26, 2024, 8:00 AM EDT - 2 years ago

SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients

Bluejay Diagnostics Announces Closing of $3.5 Million Public Offering

Jan 2, 2024, 5:58 PM EST - 2 years ago

Bluejay Diagnostics Announces Closing of $3.5 Million Public Offering

Bluejay Diagnostics Announces Pricing of $3.5 Million Public Offering

Dec 28, 2023, 8:00 AM EST - 2 years ago

Bluejay Diagnostics Announces Pricing of $3.5 Million Public Offering

Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients (SYMON Study)

Dec 27, 2023, 9:00 AM EST - 2 years ago

Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients (SYMON Study)

Bluejay Diagnostics, Inc. Reports Third Quarter 2023 Financial Results

Nov 9, 2023, 4:05 PM EST - 2 years ago

Bluejay Diagnostics, Inc. Reports Third Quarter 2023 Financial Results

Bluejay Diagnostics Announces $1.59 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Aug 25, 2023, 8:00 AM EDT - 3 years ago

Bluejay Diagnostics Announces $1.59 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Bluejay Diagnostics Announces Clinical Update and Reports Second Quarter 2023 Financial Results

Aug 16, 2023, 7:00 AM EDT - 3 years ago

Bluejay Diagnostics Announces Clinical Update and Reports Second Quarter 2023 Financial Results

Bluejay Diagnostics Updates Symphony IL-6 Regulatory Strategy

May 19, 2023, 7:00 AM EDT - 3 years ago

Bluejay Diagnostics Updates Symphony IL-6 Regulatory Strategy

Bluejay Diagnostics Reports First Quarter 2023 Financial Results

May 10, 2023, 7:30 AM EDT - 3 years ago

Bluejay Diagnostics Reports First Quarter 2023 Financial Results

Bluejay Diagnostics Reports 2022 Financial Results

Mar 20, 2023, 4:15 PM EDT - 3 years ago

Bluejay Diagnostics Reports 2022 Financial Results

Bluejay Diagnostics Signs Collaboration Agreement with Blood Centers of America

Feb 16, 2023, 8:00 AM EST - 3 years ago

Bluejay Diagnostics Signs Collaboration Agreement with Blood Centers of America

Bluejay Diagnostics, Inc. Reports Third Quarter 2022 Financial Results

Nov 9, 2022, 8:00 AM EST - 3 years ago

Bluejay Diagnostics, Inc. Reports Third Quarter 2022 Financial Results

Bluejay Diagnostics, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Aug 30, 2022, 4:05 PM EDT - 4 years ago

Bluejay Diagnostics, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Bluejay Diagnostics, Inc. to Host Key Opinion Leader Event on IL-6 Testing in Critical Care Settings: The Emerging Use of Biomarkers in Contemporary Management of COVID-19/Respiratory Failure

Aug 16, 2022, 7:30 AM EDT - 4 years ago

Bluejay Diagnostics, Inc. to Host Key Opinion Leader Event on IL-6 Testing in Critical Care Settings: The Emerging Use of Biomarkers in Contemporary Management of COVID-19/Respiratory Failure

Positive Clinical Results for Bluejay's Symphony IL-6 Test Presented at AACC 2022

Jul 27, 2022, 7:30 AM EDT - 4 years ago

Positive Clinical Results for Bluejay's Symphony IL-6 Test Presented at AACC 2022

Bluejay Diagnostics, Inc. Reports Second Quarter 2022 Financial Results

Jul 26, 2022, 4:30 PM EDT - 4 years ago

Bluejay Diagnostics, Inc. Reports Second Quarter 2022 Financial Results

Bluejay Completes Planned Clinical Studies for Symphony IL-6 Test

Jul 6, 2022, 7:30 AM EDT - 4 years ago

Bluejay Completes Planned Clinical Studies for Symphony IL-6 Test

Bluejay Diagnostics, Inc. Reports First Quarter 2022 Financial Results

Apr 20, 2022, 4:10 PM EDT - 4 years ago

Bluejay Diagnostics, Inc. Reports First Quarter 2022 Financial Results

Bluejay Diagnostics Appoints Edwin Rule as Vice President, Regulatory, Quality and Compliance

Mar 28, 2022, 7:00 AM EDT - 4 years ago

Bluejay Diagnostics Appoints Edwin Rule as Vice President, Regulatory, Quality and Compliance

Bluejay Diagnostics Appoints Kenneth Fisher as Chief Financial Officer

Mar 24, 2022, 7:00 AM EDT - 4 years ago

Bluejay Diagnostics Appoints Kenneth Fisher as Chief Financial Officer

Bluejay Diagnostics, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Mar 10, 2022, 7:00 AM EST - 4 years ago

Bluejay Diagnostics, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Bluejay Diagnostics, Inc. Announces its Pre-Submission Filing Package for the Symphony IL-6 Test is with the FDA

Jan 31, 2022, 7:00 AM EST - 4 years ago

Bluejay Diagnostics, Inc. Announces its Pre-Submission Filing Package for the Symphony IL-6 Test is with the FDA

Bluejay Diagnostics, Inc. Completes 90 Subjects in Multicenter Clinical Study Addressing Rapid IL-6 Test for COVID-19 Patients in Critical Care

Jan 13, 2022, 11:29 AM EST - 4 years ago

Bluejay Diagnostics, Inc. Completes 90 Subjects in Multicenter Clinical Study Addressing Rapid IL-6 Test for COVID-19 Patients in Critical Care

Bluejay Diagnostics, Inc. Appoints Mark Feinberg, M.D. as Chief Medical Advisor

Jan 5, 2022, 8:15 AM EST - 4 years ago

Bluejay Diagnostics, Inc. Appoints Mark Feinberg, M.D. as Chief Medical Advisor

Bluejay Diagnostics, Inc. Reports Third Quarter 2021 Financial Results

Dec 16, 2021, 9:11 AM EST - 4 years ago

Bluejay Diagnostics, Inc. Reports Third Quarter 2021 Financial Results

Bluejay Diagnostics, Inc. Announces Pricing of Upsized $21.6 Million Initial Public Offering

Nov 10, 2021, 8:15 AM EST - 4 years ago

Bluejay Diagnostics, Inc. Announces Pricing of Upsized $21.6 Million Initial Public Offering

sSwSs
sSwSs Sep. 21 at 2:57 PM
$BJDX — Bluejay Diagnostics' Symphony IL-6 product advancement and clinical study milestones contrasted with persistent financial losses and bearish technical indicators. Upside discussed: Successful completion of enrollment in the SYMON-II clinical validation study. Strengthened balance sheet to support product advancement. Risk discussed: Consistent net losses and operating losses reported annually and quarterly. Zero reported revenue and gross profit for fiscal years 2022 and 2023. Recent analyses for Bluejay Diagnostics (BJDX) covered the advancement of its Symphony™ IL-6 product towards regulatory submission, supported by a strengthened balance sheet and the successful completion of the SYMON-II clinical validation study. Concurrently, the analyses noted the company's consistent net losses, lack of revenue, and significant bearish technical indicators including prices below key moving averages and negative MACD readings.
0 · Reply
OnlyFibs
OnlyFibs Sep. 20 at 11:08 PM
$BJDX | Snapshot 📊🧪• Business: Near-patient diagnostic medical technology developer advancing the proprietary Symphony System for rapid whole-blood biomarker testing in critical care settings.• Financial Health & Pipeline: Completed enrollment in the pivotal SYMON-II clinical trial for its lead Symphony IL-6 sepsis risk test ahead of planned FDA 510(k) submission.• Bias & Conviction: Bottoming Watch | Speculative Conviction (Monitoring for a reclaim of $1.02 volume resistance following extended range contraction near $0.80 support). 🎯 Key Levels: 🐂 Bull Trigger: $1.02 / $1.25 🚀 Targets: $1.45 / $2.00 / $2.52 🛡️ Support: $0.89 / $0.80 ⚠️ Risk: $0.80 / $0.67 #BJDX #biotech #medtech #finance #hovdid
0 · Reply
STOCKSGambino
STOCKSGambino Sep. 18 at 9:24 PM
$BJDX https://x.com/StocksGambino/status/2101059714691780913
0 · Reply
azzaro2ke
azzaro2ke Sep. 18 at 8:16 PM
$BJDX 1.3?
0 · Reply
STOCKSGambino
STOCKSGambino Sep. 18 at 7:29 PM
$BJDX https://x.com/StocksGambino/status/2101029367602409536
1 · Reply
STOCKSGambino
STOCKSGambino Sep. 18 at 2:22 PM
$BJDX https://x.com/StocksGambino/status/2100953516265107628
0 · Reply
martyn78
martyn78 Sep. 16 at 7:53 AM
Been tapped into @_ProfessorGamma for a minute now. The way they spot some of these plays before they run is nuts! Wise to be paying attention to this account, give him a proper follow 👍 $NUWE / $BJDX watching
0 · Reply
PrintingGains
PrintingGains Sep. 11 at 6:39 PM
$BJDX round 2?
0 · Reply
Fsrwish
Fsrwish Sep. 11 at 3:44 PM
$BJDX sad, loose the momentum! Another reverse split?
1 · Reply
StockSenseiTrendTraders
StockSenseiTrendTraders Sep. 9 at 10:54 PM
Slow last week, slow again so far this week. There is a reason for it. PPI comes tomorrow, CPI on Friday, and FOMC is next week. A lot of traders are parked on the sidelines waiting on that outcome, and thin participation shows up in small caps immediately. $SUNE, $OLB, $MOBX, $BJDX and $YMAT still delivered. Eleven winners on twelve alerts.
0 · Reply
AtariLynx
AtariLynx Sep. 9 at 7:02 PM
$BJDX You gotta fight for your right to Naaaaaaaasdaq
0 · Reply
AtariLynx
AtariLynx Sep. 9 at 4:43 PM
$BJDX fight to survive
0 · Reply
Zackpedia
Zackpedia Sep. 9 at 4:43 PM
$BJDX Down to .9, you could’ve sold as I alerted.
0 · Reply
PierreleRat
PierreleRat Sep. 9 at 4:12 PM
$BJDX woof smells like bull trap in here lol
0 · Reply
AtariLynx
AtariLynx Sep. 9 at 2:18 PM
$BJDX fight to stay over $ 1! Fight to avoid R/S!
0 · Reply
RichJunkie25
RichJunkie25 Sep. 9 at 1:05 PM
$ANNA $BJDX $CMND $GP HAHAHAHAHA MAYBE Anna has a shot thanks to Iran going hog wild on the strait of Hormuz. I’ll give you all that. But GP/cmnd are 💩
0 · Reply
rispi
rispi Sep. 9 at 12:13 PM
$ANNA $BJDX $CMND $GP Ohhh Junky
1 · Reply
DayTrade_4Life
DayTrade_4Life Sep. 9 at 12:51 AM
💪From the Watchlist & Alerts Today 8 Sept 26: 👉See Link in Profile to Join Us. $GCDT: .44 to 1.17 (165%) $ATER: .70 to 1.02 (45%) $MOBX: 1.05 to 1.48 (40%) $PDSB: .50 to .65 (30%) $BJDX: 1 to 1.18 (18%) CDTG: 1.45 to 1.71 (17%) ARBE .94 to 1.02 (8%)
0 · Reply
STACKD0E
STACKD0E Sep. 9 at 12:03 AM
$BJDX $OCGN $RKLB $AMLX 👁️
0 · Reply
RTay1
RTay1 Sep. 8 at 9:23 PM
$BJDX Let R Rip 💥🚀
0 · Reply
eatsleeptrades
eatsleeptrades Sep. 8 at 9:22 PM
$BJDX sold here after hours. Will be back Tomorrow to see what it does
1 · Reply
focafoca99
focafoca99 Sep. 8 at 9:07 PM
$BJDX lands exclusive federal set-aside distribution rights with Lovell for VA, DoD and IHS opportunities.
0 · Reply